aplastic anemia | Page 38 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Classification of childhood aplastic anemia and myelodysplastic syndrome

Author(s): 
Niemeyer CM, Baumann I
Primary Author: 
Niemeyer CM
Journal Title: 
Hematology Am Soc Hematol Educ Program
Original Publication Date: 
Dec 2011

Hypoplastic BM disorders in children and adolescents comprise a broad spectrum of disorders. Acquired severe

Long-term follow-up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning

Author(s): 
Konopacki J, Procher R, Robin M, Bieri S, Cayuela JM, Larghero J, Xhaard A, Andreoli AL, Dhedin N, Petropoulou AD, Rodriguez-Otero P, Ribaud P, Moins-Teisserenc H, Carmagnat M, Toubert A, Chalandon Y, Socie' G, Peffault de Latour R
Primary Author: 
Konopacki J
Journal Title: 
Haematologica
Original Publication Date: 
Dec 2011

Background. Due to increased rates of secondary solid organ cancer in patients with severe

Bone Marrow Diseases: 

Functional characterization of CD4+ T cells in aplastic anemia

Author(s): 
Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Constantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F, Mufti GJ
Primary Author: 
Kordasti S
Journal Title: 
Blood
Original Publication Date: 
Dec 2011

he role of CD4(+) T-cells in the pathogenesis of AA is not well characterized. The focus of this study is to investigate the role of CD4(+) T-cells in AA with particular emphasis on CD4(+) regulatory and effector T-cell subsets and correlation with disease severity. 63 patients(48 at diagnosis) with acquired AA were studied. Numbers of Th1 and Th2-cells were significantly higher in AA compared with age matched healthy donors (HDs) (p=0.03) (p=0.006).

Bone Marrow Diseases: 

Survival After Immunosuppressive Therapy in Children with Aplastic Anemia

Author(s): 
Nair V, Sondhi V, Sharma A, Das S, Sharma S
Primary Author: 
Nair V
Journal Title: 
Indian Pediatr
Original Publication Date: 
Oct 2011

OBJECTIVE:

To determine the survival of children ?18y, treated with immunosuppresive therapy (IST) using equine antithymocyte globulin (e-ATG) and cyclosporine(CsA).
DESIGN:

Prospective data entry as per a specified format.
SETTING:

Tertiary care hospital.
PATIENTS:

From January 1998 to December 2009, 40 children were diagnosed with acquired aplastic anemia; 33 patients, who received IST, were analyzed. 31 children (94%) received one course of e-ATG and CsA. 2 patients (6%) received two courses of ATG.
INTERVENTION:

Immunosuppressive therapy using equine ATG and cyclosporine.
MAIN OUTCOME MEASURES:

Overall response and overall survival.
RESULTS:

Bone Marrow Diseases: